Loading data for ABEO — first visit, this takes a few seconds.

알림

Abeona Therapeutics Inc. (ABEO)

NasdaqCM: ABEO · 실시간 가격 · USD

6.16

+0.22 (3.70%)

종가 기준: Aug 18, 2026, 8:00 PM

3.70% (1D)

데이터 없음

매수호가	n/a
시가총액	351.09M
매출 (ttm)	25.52M
순이익 (ttm)	-62.89M
베타	1.34
EPS (ttm)	-1.21
P/E (ttm)	n/a
선행 P/E	-33.6
P/B (ttm)	2.75
P/S (ttm)	13.80
Earnings Date	Nov 11, 2026

매도호가	n/a
거래량	1,305,854
평균 거래량 (20일)	1,368,061
시가	5.90
전일 종가	5.94
일중 범위	5.87 - 6.30
52주 범위	4.00 - 7.65
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

ABEO 소개

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominan...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Sep 19, 1980

직원 수 226

상장 거래소 NasdaqCM

티커 ABEO

웹사이트 https://www.abeonatherapeutics.com

전체 기업 정보

재무 실적

2025년 Abeona Therapeutics의 매출은 5.82M로, 전년 0 대비 undefined% 증가했습니다. 순이익은 71.18M로, -211.69% 감소했습니다.

재무제표

어닝 서프라이즈

Abeona Therapeutics가 Aug 13, 2026에 분기 실적을 발표했습니다:

매출 $8.72M 예상치 하회 $0, 및 Infinity% 전년 대비 성장.

EPS -0.35 예상치 하회 -0.11, 및 25.53% 전년 대비 성장.

다음 실적 발표

Abeona Therapeutics Inc.의 실적 발표 예정일은 Nov 11, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1일 전 · GuruFocus.com

Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlights: ZEVASKYN Revenue Surges 31% ...

Despite manufacturing hiccups and patient cancellations, the company expands its treatment center network and secures CMS NTAP status to bolster market access.

5일 전 · Moby

Abeona Therapeutics Inc. Q2 2026 Earnings Call Summary

Moby summary of Abeona Therapeutics Inc.'s Q2 2026 earnings call

5일 전 · MarketBeat

Abeona Therapeutics Q2 Earnings Call Highlights

Abeona Therapeutics (NASDAQ:ABEO) reported second-quarter revenue growth from its ZEVASKYN cell therapy launch while outlining operational challenges involving patient scheduling and manufacturing tha...

2개월 전 · Simply Wall St.

Insider Favorites: Top Growth Companies For June 2026

Over the last 7 days, the United States market has experienced a 3.3% drop, yet it remains up by 22% over the past year with earnings expected to grow by 17% annually. In this context, identifying gro...

2개월 전 · Simply Wall St.

Top Growth Companies With Insider Ownership In June 2026

Over the last 7 days, the United States market has experienced a 3.3% decline, yet it remains up by 22% over the past year with earnings anticipated to grow by 17% annually in the coming years. In thi...

2 페이지 중 1

Abeona Therapeutics Inc. (ABEO)